Spero Therapeutics GAAP EPS of -$0.13 beats by $0.12, revenue of $5.44M
Source: SeekingAlpha
2025-11-13 16:13:50 ET
More on Spero Therapeutics
- Spero Therapeutics, Inc. (SPRO) Presents at IDWeek 2025 - Slideshow
- Seeking Alpha’s Quant Rating on Spero Therapeutics
- Historical earnings data for Spero Therapeutics
- Financial information for Spero Therapeutics
Read the full article on Seeking Alpha
For further details see:
Spero Therapeutics GAAP EPS of -$0.13 beats by $0.12, revenue of $5.44M
Spero Therapeutics Inc.
NASDAQ: SPRO
SPRO Trading
5.71% G/L:
$2.405 Last:
276,692 Volume:
$2.31 Open:
SPRO Latest News
December 19, 2025 08:00:00 am
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
November 13, 2025 04:05:00 pm
Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update
SPRO Stock Data
$132,679,040
44,000,989
3.11%
13
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
